I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ESMO 2026
Roche and Genentech at

ESMO 2026

October 23 - October 27
Madrid, Spain / Virtual (Hybrid)
esmo.org
We will be contributing to topics related to
Oncology
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
07:00 AM
Duration 60mins Madrid, Spain
Comparison of Cumulative Incidence of Grade 3/4 and Serious Adverse Events Between Subcutaneous and Intravenous Formulations of Three Oncology Monoclonal Antibodies
Mauricio Burotto, Saad Z. Usmani, Saby George, Maria T. Bourlon, Federico Cappuzzo, Charles Theuer, Ruiyun Jiang, Ruchi Shah, Lucia Xiaoyan Liu, Esther Shearer-Kang, Luis Herraez-Baranda, Laurence Albiges
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:15 PM
Duration 45mins Madrid, Spain
Tambotatug Pelitecan (YL201): Analyses of interstitial lung disease in patients with advanced solid tumours from Phase 1/2 studies
Fu Siqing, Anjali Rohatgi, Stephen Liu, Jon Zugazagoitia, Bernard Doger de Speville, Valentina Gambardella, Shiraz Sen, Xiaodong Tang, Xiangilao Meng, Wu Zhuang, Yulong Zheng, Dingwei Ye, Steve Chin, Xian Zhang, Sophie Sun, Mark Yan, Pao-Chen Li, Vaikunth Cuchelkar, Li Zhang
Oncology - Haematology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 45mins Madrid, Spain
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC) in patients (pts) with advanced solid tumors
Shiraj Sen
Oncology - Haematology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:20 PM
Duration 5mins Madrid, Spain
Patient (pt)-reported outcomes (PROs) from the Phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC)
Gustavo Werutsky, Aditya Bardia, Charles E. Geyer, Jr., Mothaffar F. Rimawi, Sara A. Hurvitz, Miguel Martín, Nadia Harbeck, Kyung Hae Jung, Sherene Loi, Shigehira Saji, Dawn Hershman, Lesley Fallowfield, Gregory A. Vidal, Fatima Cardoso, Kyong Hwa Park, Laura M. Spring, Sheetal Patel, Ching-Wei Chang, Nimali P. Withana, Peter Schmid
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:25 AM
Duration 5mins Madrid, Spain
Retrospective exploratory biomarker (BM) analyses from evERA Breast Cancer (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) setting
Sara M. Tolaney, Jackson Liang, Walter C. Darbonne, Erica L. Mayer, Miguel Martin, Gregory A. Vidal, Luca Moscetti, Komal L. Jhaveri, Adam Brufsky, William J. Gradishar, Andreas Schneeweiss, Joyce A. O’Shaughnessy, Max Dieterich, Lisa H. Lam, Tharu Fernando, Hope S. Rugo
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 AM
Duration 45mins Madrid, Spain
Real-world eligibility for DESTINY-Breast11 (DB-11) neoadjuvant escalation criteria and outcomes of DB-11-eligible vs DB-11-ineligible patients with HER2-positive early breast cancer (HER2+ eBC)
Paolo Tarantino, Elsa García Hernández, Erika Schirghuber, Ibrahim M. Abbass, Alisan Zirtiloglu, Thibaut Sanglier
Oncology - Haematology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 45mins Madrid, Spain
BREnnA: Phase II/III randomised study of ZN-A-1041 or tucatinib (TUC), in combination with trastuzumab + capecitabine (HX), in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (HER2+ LA/mBC) with or without central nervous system (CNS) metastases
Nancy U. Lin, Giampaolo Bianchini, Erika Hamilton, Weize Huang, Adam Knott, Julia Maués, Filippo Montemurro, Volkmar Müller, Mahesh Shivhare, Gregory Vidal, Binghe Xu, Eleonora Restuccia, Javier Cortés
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 45mins Madrid, Spain
Updated interim analysis of giredestrant (GIRE) + inavolisib▼ (INAVO) in MORPHEUS Breast Cancer (BC): A Phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative, locally advanced/metastatic BC (ER+, HER2– LA/mBC)
Hope S. Rugo, Cristina Saavedra, Kyung Hae Jung, Melinda L. Telli, Amir Sonnenblick, Einav Gal-Yam, Jing Zhu, Annie Collier, Miranda Craft, Aaron Galluzzi, Huy X. Ngo, Richard Schwab, Begoña Bermejo De Las Heras
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:30 AM
Duration 5mins Madrid, Spain
Immunogenomic signature associated with ICI-related pneumonitis in non-small-cell lung cancer (NSCLC) patients
Naidoo J, Guinot F, Mohindra R, Roth AB, Lyalina S, Quartey G, Torres Florez S, Prabhakaran R, MacPherson C, Chandler S
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 90mins Madrid, Spain
Next-era strategies in HR+ HER2– early breast cancer: Optimising endocrine therapy
Nicholas C. Turner, Miguel Martín, Erica L. Mayer
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Madrid, Spain
Next-era strategies in HR+ HER2– early breast cancer: Optimising endocrine therapy
Nicholas C. Turner, Miguel Martín, Erica L. Mayer
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 60mins Madrid, Spain
Testing serum autoantibodies and oncoproteins in patient selection for Lung Cancer Screening: the iDx Lung study
D. Muller, S. Wilding, T. Oliver, V.M. Goss, A. Cazaly, J. Walters, A. Coleman, I. Macdonald, B. Wehnl, A. Heinson, M. Lichtenfield, A. Hicks, P.A.J. Crosbie, M.E.J. Callister, R.D. Neal, G.O. Griffiths, P.W.M. Johnson
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:30 PM
Duration 12mins Madrid, Spain
Krascendo 1: efficacy and safety of divarasib vs sotorasib or adagrasib in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC
Skoulidis F, Ahn MJ, Gadgeel S, Popat S, Reinmuth N, van Veggel B, Bozorgmehr F, Bray VJ, Duruisseaux M, Iams WT, Mazieres J, Bonanno L, Decoster L, Wang B, Hu Y, Shagan SM, Lam V, Osaghae U, Hoang T, Solomon BJ
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 AM
Duration 45mins Madrid, Spain
Alectinib and local therapy for optimal treatment in ALK-positive non-small cell lung cancer (ALTHEO study: NEJ069)
Toshiya Fujisaki, Takehiro Tozuka, Susumu Takeuchi, Aki Kubota, Gen Kida, Yuta Yamanaka, Ou Yamaguchi, Hiroki Iida, Hiroaki Ikushima, Satoshi Takahashi, Ryota Saito, Tetsuo Tani, Go Saito, Daiki Murata, Katsuya Yanagisawa, Hiroyasu Kaneda, Shinya Fujioka, Kunihiko Kobayashi, Makoto Maemondo, Masahiro Seike
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 AM
Duration 45mins Madrid, Spain
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II–IIIB KRAS G12C+ non-small cell lung cancer (NSCLC)
Solange Peters, Narjust Florez, Jonathan Spicer, Erin A. Gillaspie, Dwight Owen, Yi-Long Wu, Diana Ndunda, Sebastian Heinzmann, Youyou Hu, Celina Ngiam, Ryan Chang, Patrick Forde
Oncology - Haematology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 45mins Madrid, Spain
Tambotatug pelitecan (YL201): Efficacy and safety in locally advanced/metastatic NSCLC from a phase 1 study
Stephen V. Liu, Valentina Gambardella, Bernard Doger de Spéville, Siqing Fu, Deborah Doroshow, Shiraj Sen, Ulka Vaishampayan, Steve Chin, Xian Zhang, Ying Sun, Barbara Gitlitz, Mark Yan, Anjali Rohatgi
Oncology - Haematology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 45mins Madrid, Spain
ReaLuNGS: Real-world molecular testing and treatment patterns in advanced non-small cell lung cancer (NSCLC) across Latin America
Adam Gondos, Bettina Buchheister, Breno Jeha Araujo, Delfina Peralta Tanco, Juan David Florez Arango, Marcela Vilariño Pereda, Rodrigo Dienstmann, Sebastian Camerlingo
Oncology - Haematology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Madrid, Spain
Advancing the Frontiers of Lung Cancer Care
Stephen V Liu, Ferdinandos Skoulidis, Margarita Majem, Terri Conneran
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Madrid, Spain
Watch: Advancing the Frontiers of Lung Cancer Care
Stephen V Liu, Ferdinandos Skoulidis, Margarita Majem, Terri Conneran
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.